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During the past three decades, the deleterious consequences of Chornobyl accident including carcinogenic effects in the people who 
were accidentally exposed to radiation have been intensively studied. In particular, recent studies provided increased knowledge of the 
molecular pathogenesis of thyroid tumors in children exposed to Chornobyl fallout. The risk of several forms of leukemia including 
myelodysplastic syndromes is elevated in Chornobyl liquidators. Furthermore, the upward trends of increases in a variety of other 
tumors including breast cancer, cancers of central nervous system and renal cancer have been reported in the persons exposed to Chor-
nobyl fallout. There is growing evidence that insufficient apoptosis allows irradiated cells to survive and thereby contributes to carci-
nogenesis. The purpose of the present survey is to summarize the recent findings related to apoptotic biomarkers among cancer patients 
from the different populations affected by the Chornobyl catastrophe. Among the particularly radiosensitive cancer sites, we focused 
on thyroid cancer and leukemia. Several genes and/or proteins controlling apoptosis directly or indirectly have been incorporated into 
the analysis. The data reviewed here provide a mechanistic link between the apoptosis alterations and development of radiation-relat-
ed cancer in the 30-year post-Chornobyl period. We suggest that the type of mutations arising from misrepair of DNA double strand 
breaks (gene fusion and amplification) is the initial signature event in radiation-induced thyroid cancer. Much work has to be done 
over the next years to elucidate central questions related to the nature of human radiation carcinogenesis. This article is part of a Spe-
cial Issue entitled “The Chornobyl Nuclear Accident: Thirty Years After”.
Key Words: Chornobyl nuclear power plant accident, ionizing radiation, radiation-induced carcinogenesis, apoptotic biomarkers, 
Chornobyl-affected human populations, thyroid cancer, leukemia, myelodysplastic syndromes, telomere, microRNA.
INTRODUCTION
On April 26, 2016 the world marked 30 years 
since the Chornobyl nuclear power plant accident 
in Ukraine — the disaster that affected millions of people 
of all ages in Belarus, Ukraine, and the Russian Federa-
tion as well as vast areas of Europe and the northern 
hemisphere [1–4]. In 2006, the International Atomic 
Energy Agency classified the Chornobyl accident as 
“the greatest nuclear catastrophe in human history” [5]; 
a perception that remains valid even when considered 
the atomic bombings in Hiroshima and Nagasaki. In ad-
dition to the scale, the radiation exposure from Chor-
nobyl fallout differed from that from the atomic bombs; 
respectively, protracted/low dose vs. acute high dose/
dose rate, mixed α + β + γ radiation vs. mostly γ + n, 
mostly internal vs. mostly external exposure, patchy vs. 
uniform spread of radioactivity, and the size of exposed 
population > 107 vs. ~ 105.
Technical aspects of the Chornobyl nuclear power 
plant accident and radioactive releases have been 
thoroughly described in a number of publications [1–3] 
but a short account is given here to help to appreciate 
the radiological impact. Briefly, human error during 
experimental operation and some reactor design 
flaws led to catastrophic overheating of the fuel and 
thermal destruction of the primary coolant system. 
The combination of these factors resulted in at least 
one (steam) explosion that dispersed reactor debris 
and ignition of graphite moderators. Radionuclides 
released from the steam explosion included very short 
lived fission products (half-lives in the order of seconds 
and minutes), which resulted in very high dose rates 
immediately around the reactor site. After the initial 
release, further releases of radionuclides occurred over 
another10 days due to the graphite fire; Table 1 lists 
selected radionuclides released due to the Chornobyl 
accident [2]. Radioactive emission from the reactor 
moved with prevailing winds and spread in a spotty 
pattern over the territories of several countries. Heavy 
rainfalls exacerbated radioactive fallout resulting in the 
contamination of groundwater and soil. Active emission 
into the atmosphere ceased after a sarcophagus around 
the destroyed reactor was completed in November 
1986 [1].
Referring to Table 1, the main nuclides of concern 
for the dose received by the exposed population are 
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iodine-131, cesium-137, cesium-134, strontium-90. The 
release of radioactive iodine isotopes (iodine-131 and 
-133) was of immediate significance in the first few 
weeks after the accident, but became less significant 
over time, given their short half-lives. Cesium-137 will 
continue to be the most significant radionuclide, as far 
as exposure to radiation is concerned. The nuclear fuel 
particles, strontium-90, plutonium-241, and α-emitting 
actinides (not listed in Table 1) were deposited at high 
concentration within about a 20-km zone around the 
reactor. Plutonium-241 decays to americium-241 which, 
in turn, decays by α emission with a by-product 
of γ-rays. The total activity of americium-241 in the en-
vironment will reach a maximum in the year 2058 after 
which will slowly decline.
The major Chornobyl-affected groups represent 
registered accident recovery workers, evacuees, 
children and adults from areas contaminated by radio-
nuclides (Table 2). Among 530,000 workers who were 
engaged in recovery operations (“liquidators”; the offi-
cial term used in the former Soviet Union) the individuals 
who took part in the activities in 1986–1987 received 
the highest whole body effective doses exceeding 
500 mSv [2, 3]. The average internal dose to the thyroid 
of liquidators was 0.21 Gy. It has been difficult to confirm 
the validity of the results that have been reported for 
a variety reasons, including lack of dosimetry equip-
ment for measuring mixed α + β + γ fields [6]. About 
270,000 people continue to live in strictly controlled 
areas where cesium-137 contamination in soil exceeds 
555 kBq/m2. This review will focus on apoptotic markers 
in cancer patients from the above-mentioned groups 
affected by the Chornobyl catastrophe.
RADIATION-INDUCED CARCINOGENESIS
There is a long history of a link between exposure 
to ionizing radiation and an elevated incidence of can-
cer [7]. Ionizing radiation is defined as electromagnetic 
radiation (e.g., γ-rays) or particulate radiation (e.g., 
electrons or α-particles) that has sufficient energy 
to remove electrons from molecules (e.g., DNA) and 
their local environment. Free electrons, in turn, can 
damage human cells. If cellular damage is not fully and 
perfectly repaired, it may result in cell death, or it may 
result in a viable but modified cell that retains molecular 
alterations as a legacy of radiation exposure. The two 
outcomes have different health consequences for indi-
viduals whose cells were damaged by ionizing radiation. 
Cell death results in the loss of tissue function if a suf-
ficiently large number of cells have been eliminated; 
illustrative examples include acute radiation syndrome, 
microcephaly, and growth and mental retardation in the 
children of mothers exposed to radiation. However, if the 
irradiated cell remains viable but modified at molecular 
and biochemical levels, the health consequence of pri-
mary concerns is the induction of cancer. Leukemia and 
cancer of the thyroid, lung, and breast have been con-
sistently associated with ionizing radiation exposure [8].
Cancer induction is a stochastic or probabilistic 
(random) process. This means, as Eric Hall put it, that 
“a cancer induced by 1 Gy is no worse than one induced 
by 0.1 Gy”, but “of course the probability of its induction 
is increased” [9]. Epidemiological studies generally 
show that (i) the probability of solid cancer induction, 
or risk, increases linearly with increasing radiation dose 
with no dose threshold (a linear-quadratic relationship 
between dose and risk for leukemia) [8], and (ii) ex-
posure to ionizing radiation can lead to the age-/time-
Table 1. Main radionuclides released during the Chornobyl accident (26 April 1986 — 6 May 1986) [5]
Isotope Half-life Decay mode Principal route/target/health hazard
Krypton-85 11 years β–, γ, to Rb-85 Inhalation of air/multiple organs (fat)/asphyxiant
Internal irradiation from β + γ
Xenon-133 5 days β–, γ, to Cs-133 (stable) Inhalation of air/lung
Iodine-131 8 days β–, γ, to Xe-131 Ingestion of contaminated food (milk)/thyroid (cancer)
Ruthenium-106 374 days β–, γ, to Rh-106 Inhalation of air/lung
Cesium-134 2 years β–, γ, to Ba-134 Ingestion of contaminated food (vegetable, meat)
External irradiation from β + γ
Cesium-137 30 years β–, γ, to Ba-137 Ingestion of contaminated food (vegetable, meat)
External radiation from β + γ
Strontium-90 29 years β–, γ, to Y-90 Inhalation of air
Ingestion of contaminated water, food/bone (leukemia)
Plutonium-241 14 years β–, γ, to Am-241 Inhalation of air/lung
Wound/ingestion of contaminated water, food (low hazard)
Plutonium-242 373,300 years α, to U-238 Inhalation of air/lung
Ingestion of contaminated water, food (low hazard)
Table 2. Populations radiologically affected by the Chornobyl accident (based on the data in [2] and [3])
Population group Population size Thyroid dose (Gy)* Effective dose in 1986–2005 (Sv)* Comments
Emergency workers and reac-
tor staff
600 0.8–16 Gy (external)
0.021 to 4.1 Gy (internal)
26 April to 6 May 1986
Recovery operation workers  
(“liquidators”)
530,000 < 0.15 to 3 Gy 120 mSv
< 10 mSv to > 500 mSv
1986–1990
1986–1987
Evacuees 115,000 490 mGy (< 50 mGy to 5 Gy) 31 mSv 1986–2005
Inhabitants of contaminated areas 
of Belarus, the Russian Federation, 
and Ukraine
6,400,000 102 mGy (> 1 Gy for 0.7% 
population)
9 mSv 1986–2005
The average thyroid dose 2–4 times 
higher in pre-school children
Inhabitants of Belarus, the Russian 
Federation and Ukraine
98,000,000 16 mGy 1.3 mSv 1986–2005
Includes contaminated areas in the Rus-
sian Federation, Ukraine and Belarus
Note: *radiation doses to tissue are expressed in terms of absorbed dose in units of Gray (Gy) while doses to the whole body from external and internal irradia-
tion are expressed in terms of the weighted quantity, effective dose, in units of Sievert (Sv).
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dependent development of a wide range of tumors that 
are indistinguishable from those arising spontaneously 
in nonirradiated populations [8]; studies with animal 
and cellular model systems provide essentially the 
same message [7]. Thus it could be concluded that the 
process of cancer development after ionizing radiation 
largely mirrors the process of spontaneous carcino-
genesis. Over the last decade, sequencing of more 
than 22,000 cancers revealed more than 3,000,000 al-
terations in malignant tumors [10–14]. A systematic 
analysis of these genetic alterations has advanced our 
understanding of the relationship between genotype 
(genetic susceptibility and somatic mutations) and 
phenotype (tumor development and growth) [13, 14]. 
As discussed later, similar multilevel integrated ap-
proaches have been used to identify alterations that 
could be characteristic of radiation exposure from the 
Chornobyl radioactive fallout.
The current paradigm in cancer biology is that car-
cinogenesis is a multistage process. The implication 
is that several distinct events separated in time are re-
quired to complete the long march toward tumorigene-
sis [15–18]. This idea is now more than 70 years old and 
is exemplified by the skin cancer experiments in mice 
that introduced the concepts of initiation, promotion, 
and progression as stages of tumor development [19]. 
Within the framework of the initiation-promotion-pro-
gression model, ionizing radiation is assumed to act 
as an initiating agent [7, 8].
The discovery of DNA as the molecular carrier 
of heredity [20] led to the hypothesis that cancers are 
abnormal clones of cells characterized by and caused 
by abnormalities in hereditary material that originated 
from a single aberrant cell [21]. This hypothesis is sup-
ported by the demonstration that (i) transfer of the total 
DNA isolated from human cancers into phenotypically 
normal cells can convert them into cancer cells [22, 23], 
and (ii) agents that damage DNA and generate gene 
and chromosomal mutations in somatic cells also cause 
cancer [24]. There is a weight of evidence that ionizing 
radiation is responsible for DNA double-strand breaks 
resulting in the changes biologically relevant for initia-
tion of carcinogenesis [8]. Putative changes observed 
in cancers include among others chromosome rear-
rangements, such as translocations including formation 
of chimeric genes [25] and gene amplifications [26–28], 
all associated with etiology of Chornobyl fallout-associ-
ated hematopoietic and pediatric thyroid malignancies.
Chromosome rearrangements contribute to tu-
morigenesis by altering the dosage of oncogenes and 
tumor suppressor genes [29]. Specifically, transloca-
tions generally fuse two genes to create an oncogene 
or can inactivate a tumor suppressor gene by truncating 
it or by separating it from its promoter. Amplifications usu-
ally contain an oncogene whose gene product is abnor-
mally active because the tumor contains 10 to 100 cop-
ies of the gene per cell, compared with the two copies 
present in normal cells. Gain and loss of chromosomal 
material in neoplastic cell populations is considered 
to be a process of diversification that leads to the survival 
of the fittest clones [30]. Such cells are thought to lose 
any cellular function that has proved to be non-essential 
for their viability, that is, does not increase their cellular 
fitness [17, 18, 21, 30]. For example, cells displaying 
a fitness phenotype tolerate progressive chromosomal 
instability, tolerate metabolic stress, glucose deprivation, 
hypoxia, oxidative stress in microenvironment, tolerate 
mistakes while replicating DNA or during division, and 
abrogate checkpoints which exist to slow down their 
growth or make them to commit suicide (apoptosis) 
under such circumstances [13, 16, 30, 31].
MOLECULAR MARKERS OF APOPTOSIS
Apoptosis is the most investigated mode of regulated 
cell death and is characterized by a highly ordered cel-
lular destruction in response to internal and/or external 
stimuli. Apoptotic cell death is distinguished by unique 
morphological and biochemical characteri stics. Ac-
cording to the functional classification of cell death 
subroutines proposed by the Nomenclature Committee 
on Cell Death (2012), four major modes of apoptotic 
cell death could be delineated: (i) extrinsic apoptosis 
by death receptors; (ii) extrinsic apoptosis by depen-
dence receptors; (iii) caspase-dependent intrinsic 
apoptosis; and (iv) caspase-independent intrinsic apop-
tosis [32]. Receptor-dependent apoptosis is mediated 
by death receptors (TNFR-1, Fas, TRAIL-R1, TRAIL-R2) 
[33] or dependence receptors (DCC, UNC5, Patched, 
TrkC, and others) [34], representing cell surface trans-
membrane proteins. Upon the binding of death ligands 
to their respective death receptors dynamic multiprotein 
complex known as death-inducing signaling complex 
(DISC) is assembled. Besides death receptors, DISC 
comprise the adaptor Fas-associated protein with death 
domain (FADD), pro-caspase-8 (or -10), and the cellular 
FLICE-like inhibitory protein (cFLIP) [33]. On recruitment 
to the DISC, the pro-caspase-8 (or pro-caspase-10) 
forms homodimers resulting to caspase activation at the 
DISC. Activated caspase-8 then initiates the caspase 
cascade by cleaving downstream effector caspases 
or the BH3 interacting domain death agonist (BID) that 
ultimately leads to apoptosis. Mechanisms of apoptosis 
induction mediated by dependence receptors or death 
receptors are principally different. Moreover, proapop-
totic signaling pathways are not similar for various de-
pendence receptors [34]. For example, in the absence 
of its ligand Sonic Hedgehog, the dependence recep-
tor Patched triggers apoptosis through ubiquitination 
(by E3 ubiquitin ligase NEDD4) and activation of initiator 
caspase-9 [35]. The caspase-dependent intrinsic path-
way is activated following cellular stress, which results 
in mitochondrial outer membrane permeabilization 
(MOMP) facilitating the release of pro-apoptotic proteins 
from the mitochondrial inner membrane space into the 
cytosol. In particular, cytosolic cytochrome c triggers the 
oligomerization of apoptotic peptidase activating factor 
1 (APAF-1), which recruits pro-caspase-9 into the apop-
tosome, the activation platform for caspase-9. Active 
caspase-9 then directly cleaves and activates effector 
Experimental Oncology 38, 224–237, 2016 (December) 227
caspases-3 and -7, resulting in cleavage of many vital 
cellular proteins and subsequent apoptosis.
Caspase-independent mechanisms of cell death 
may be initiated by active (e.g., apoptosis-inducing 
factor) or passive (e.g., ATP depletion) mechanism. 
The active initiation of apoptosis-associated DNA frag-
mentation is mediated by translocation of apoptosis-
inducing factor and endonuclease G to the nucleus 
following MOMP [36]. Mitochondrial high temperature 
requirement protein A2 (HTRA2) possessing serine 
protease activity also plays as direct effector of cas-
pase-independent apoptosis [36]. Other known play-
ers of caspase-independent apoptosis are lysosomal 
cathepsins. After translocation into the cytosol follow-
ing lysosomal membrane permeabilization cathepsins 
process their substrates to promote apoptotic signal-
ing [37]. In addition to their involvement in caspase-
independent cell death, cathepsins can also directly 
digest and activate caspases.
It is noteworthy that the release of apoptosis-related 
proteins from mitochondria upon both caspase-depen-
dent and -independent apoptosis is regulated by the 
BCL-2 protein family composed of one antiapoptotic 
(BCL-2, BCL-XL, BCL-W, MCL-1, and A1) and three pro-
apoptotic (effectors such as BAX, BAK, BOK; activators 
such as BID, BIM, PUMA; and sensitizers such as BAD, 
BIK, NOXA, HRK, BNIP3, and BMF) subgroups [38, 39]; 
in addition to its activity as a sensitizer, NOXA can also 
act as an activator protein [38]. The functional balance 
between prosurvival and proapoptotic members of the 
BCL-2 family of proteins determines the fate of a cell. 
Furthermore, caspase activation and function are con-
trolled by the inhibitor of apoptosis proteins (IAPs) [40] 
that in turn can be antagonized by mitochondrial pro-
teins HTRA2 and direct IAP-binding protein with low PI 
(DIABLO) upon their translocation to the cytosol caused 
by apoptotic stimulus [32]. The cellular tumor antigen 
p53 is one of key regulators of the cellular response 
to DNA damage, hypoxia, nutrient deficiency, and many 
other cytotoxic stresses, including ionizing radiation. 
In response to cell stress signal, p53 induces cell-
cycle arrest, senescence (loss of proliferative potential) 
or apoptosis. To date, the p53-mediated apoptotic path-
ways functioning in both transcription-dependent and 
-independent manner are well established (for review, 
see [41]). Given that molecular network responsible for 
regulating and exe cuting apoptosis consists of plethora 
of the specific components (around 300 genes in mam-
mals [42]), any of them could be represented as a candi-
date apoptosis marker. Moreover, the expression of each 
gene enco ding an apoptotic protein might be regulated 
by long and short non-coding RNAs. The involvement 
of long non-coding RNAs and microRNAs (miRNAs) 
in apoptosis has been intensively explored [43, 44].
Because resistance to apoptotic cell death is a hall-
mark of cancers [17, 18], the identification of apoptosis 
biomarkers has become an interesting topic in cancer 
research. The major alterations in both receptor-de-
pendent and -independent apoptotic pathways, which 
are believed to play a significant role in tumorigenesis 
and resistance to anticancer treatment, are depicted 
in Fig. 1. A large body of clinical data indicates that 
certain apoptosis-related genes and/or proteins may 
be useful for early and differential diagnosis, prognosis, 
and treatment response to specific therapies [46–52]. 
Several most promising apoptosis markers in post-
Chornobyl cancers will be discussed in the following 
sections.
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Fig. 1. Major alterations in genes and/or proteins contributing to evasion of apoptosis and carcinogenesis. Figure was reproduced 
from [45] distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0)
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APOPTOTIC MARKERS IN CANCER AFTER 
THE CHORNOBYL ACCIDENT
Thyroid cancer
The accident in the Chornobyl nuclear power 
plant in 1986 has been shown to lead to excessive 
numbers of thyroid cancers among children exposed 
to the radioactive fallout [2–5]. Clear dose depen-
dence of childhood thyroid cancers has proven that 
radiation exposure is the primary cause of thyroid 
cancer induction [53–55]. This is supported further 
by: (i) the temporal patterns in terms of age and time 
after exposure; namely, the increase started to ap-
pear 4–5 years after the accident in children born 
before but not after the accident, and no increase 
was observed in exposed adults (i.e. liquidators and 
individuals who lived in areas of high contamination); 
(ii) Chornobyl-related dose response for thyroid 
cancer is similar to that described for atomic bomb 
survivors and individuals who have received medical 
irradiation to the thymus and face [56]. As of June 
2016, a causal effect of the Fukushima Daichi nuclear 
power plant accident on thyroid cancer incidence 
in the Japanese children is debatable five years after 
the accident [57, 58].
Referring to Table 2, relatively short-lived iodi-
ne-131 and iodine-133 were the main contributors to the 
internal radiation exposure to the thyroid within a few 
weeks after the accident. Since 1987, ionizing radiation 
exposure was due to cesium-137 and -134 and stron-
tium-90 incorporation in foodstuffs (milk, meat, pota-
toes, root vegetables, wild mushrooms, berries, etc.) 
as well as inhalation of aerosols containing radioactive 
plutonium and other actinides [3–6].
The Chornobyl childhood thyroid cancer studies 
provide unique insights into the molecular mecha-
nisms of radiation-induced carcinogenesis because 
(i) the compendium of genetic alterations in sponta-
neous thyroid cancers by the Cancer Genome Atlas 
(TCGA) project [59] provides a ready framework 
of reference for genetic alterations in radiation-
induced thyroid cancers; (ii) epidemiological, radio-
biological, genetic, and dosimetric data can be inte-
grated for individual cohorts [53, 55, 60, 61]; (iii) the 
observed high incidence of the disease in pediatric 
patients who lived in the Chornobyl fallout areas 
could be attributed to radiation exposure because 
of low background of spontaneous disease [59, 62]; 
(iv) it is an excellent in situ model of radiation-induced 
carcinoma owing to the fact that most thyroid cancers 
(except medullary carcinoma) originate from unicel-
lular follicular epithelium of normal thyroid (there are 
no corresponding in vitro neoplastic transformation 
assays; for example [63]; radiation-induced carcino-
mas predominate over sarcomas [1]).
In 1987, Fusco et al. identified the first human on-
cogene associated with thyroid cancer [64] using DNA 
transfection analysis on immortalized rodent cells [22]. 
Of note, the patient who donated thyroid tissue samples 
for the analysis had been accidentally exposed to a high 
dose of ionizing radiation seven years before diagnosis 
of thyroid malignancy. It had been established later that the 
transforming gene is an activated the RET proto-oncogene 
[65]. The RET gene codes for a cell membrane receptor 
tyrosine kinase [66]. In papillary thyroid carcinoma, RET 
is activated via chromosomal rearrangements, which re-
sults in fusion of the intracellular tyrosine kinase domain 
of RET and portions of various genes, creating the family 
of chimeric proteins termed RET/PTC. Table 3 lists RET-
fused and other gene rearrangements involving BRAF, 
NTRK, and PPARγ in thyroid carcinoma after Chorno-
byl [62, 67–76]. As discussed later, these rearrangements 
may cause both the gain of oncogenic functions of RET, 
BRAF, NTRK, and PPARγ and the knockout of the tumor 
suppressor function of partner genes.
The fused forms of RET involving CCDC6 (PTC1) 
or NCOA4 (PTC3 and PTC4) are considered the genetic 
markers of childhood thyroid carcinoma associated with 
exposure to ionizing radiation [60–62]. For example, 
in a series of 59 post-operative thyroid carcinomas 
obtained from the children in Belarus during the first 
post-Chornobyl decade, 72% tumors analyzed had 
this type of RET arrangements compared to 20% RET/
PTC fusions in non-irradiated populations. Although 
radiogenic origin for these thyroid cancers has been 
questioned [62, 77–80], the high degree of specificity 
of gene rearrangements catalogued in Table 3 strongly 
argues otherwise. Mechanistically, nonrandom and 
simultaneous breakage of participating genes as well 
as their recombination vs. randomness of ionizing 
radiation-induced DNA double strand breaks is quite 
plausible when tissue-specific architecture of nuclear 
chromatin is taken into account [81]. A more interest-
ing aspect, however, is an indication of the molecular 
mechanisms of the initiating radiation effects [8, 25, 81]. 
This possibility is nicely illustrated by the observation 
that experimental overexpression of RET/PTC1 or RET/
PTC3 oncogenes in thyroid follicular cells is insufficient 
alone to induce a full-blown thyroid cancer, unless anti-
death and proliferation programs are also activated [82, 
83]. Finally, some rearranged forms in Table 3 define 
molecular subtypes of the Chornobyl fallout-induced 
thyroid cancers; specifically, RET and NTRK fusions 
characterize a subset of papillary thyroid carcinoma [61, 
67, 70], while PAX8/PPARγ fusions characterize subset 
of follicular thyroid carcinoma [62, 67, 68].
As reported [80, 84–86], a radiation-specific DNA 
copy number gain of chromosome 7 band q11 and 
mRNA overexpression of the CLIP2 (CAP-Gly domain 
containing linker protein 2) gene located within the 
amplified band are novel potential markers of radia-
tion exposure in post-Chornobyl thyroid carcinomas 
in Ukrainian and Russian children [87]. As in the case 
of chromosomal aberrations [88], the gene amplifica-
tion is a consequence of misrepair of ionizing radiation-
induced DNA double strand breaks [27, 28]. Copy num-
ber alterations, present in 33% of radiation-exposed 
cases and absent in all non-exposed cases [87], 
suggest a strong correlation with the tumor causality 
[83, 84]. However, CLIP2 amplification in the exposed 
vs. non-exposed groups coexists with RET rearrange-
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ments [80]; thus, rather than having a stand-alone role, 
CLIP2 may contribute to the thyroid cancer develop-
ment in concert with other changes in the genome that 
enhance or inhibit some aspects of carcinogenesis, 
e.g., the ability of initiated cells to bypass or disable the 
apoptotic machinery [17].
A role in apoptosis for the rearranged genes is com-
plex because both functions of genes that form fusion 
and functions of partners with which they fuse may 
be affected [89, 90]. Several observations indicate 
that the transforming potential of fusion genes is not 
limited to the kinase activation. In fact, the normal cel-
lular function of each respective fusion partner that 
contributes to a fusion protein is severely disrupted 
(Table 3 based on data in [91, 92]). Full-length wild-
type CCDC6 (coiled-coil domain containing protein 6) 
is a pro-apoptotic phosphoprotein that negatively regu-
lates CREB1-dependent transcription and as a substrate 
of ATM serine/threonine kinase is responsive to ionizing 
radiation-induced DNA damage (the first neighborhood 
network [93] of wild type CCDC6 is shown in Fig. 2). 
However, a truncated form corresponding to the frag-
ment included in the RET/PTC1 fusion gene promotes 
cell survival [94]. In addition, expression of a truncated 
CCDC6 may act as a dominant, negative inhibitor of the 
wild-type CCDC6 protein, thus inhibiting apoptosis [94]. 
Further, Merolla and co-workers [95, 96] demonstrated 
that CCDC6 deficiency in cancers that carry CCDC6 fu-
sion affects ATM-, p53- and PP4-mediated responses 
to DNA damage, specifically the γH2AX foci formation, 
repair of DNA double-strand breaks, and integrity of the 
G2/M checkpoint thereby allowing the cell to enter mi-
tosis with DNA damage. Similarly, PRKAR1A and the 
TRIM gene family which contribute to RET/PTC2, RET/
PTC6 and RET/PTC7 (Table 3), normally act as cancer 
suppressors, a function likely to be abrogated by their 
disruption during fusion gene generation. The wild-type 
TRIM24 protein in collaboration with TRIM33 is involved 
in p53-regulated pathways such as apoptosis and the 
DNA damage response as well as transcription regu-
lation via core histone modification and binding [97]. 
By inference, these pathways may become deregulated 
which enhances the opportunity to destabilize the ge-
nome [13, 14, 16, 17].
An apoptotic footprint has been seen in some stud-
ies of the molecular pathology of thyroid cancer. Dinets 
et al. [98] searched for markers of proliferation and 
apoptosis in a cohort of 70 Ukrainian adult thyroid can-
cer patients exposed to the radioactive fallout from the 
Chornobyl accident during their childhood (all patients 
were 18 years of age or younger in 1986 and diagnosed 
between 2004–2008). The BCL2 protein was found 
to be overexpressed by immunochemistry in 90% papil-
loma thyroid cancers suggesting anti-apoptotic signal-
ing in the tumors carrying the BRAF point mutations 
(T → A at position 1799, also called V600E), associated 
with non-radiogenic etiology [58, 62, 78]. A similar in-
crease in BCL2 mRNA expression has been observed 
among 15 differentially expressed genes between ra-
diation-induced and sporadic papilloma thyroid cancer 
Table 3. Chromosomal rearrangements in childhood thyroid cancer related to the Chornobyl accident
Gene Partner gene Symbol of partner gene Change in the genome Function of wild-type partner protein
RET/PTC1 Coiled-coil domain containing 6 CCDC6 (also known 
as H4 or D10S170)
inv(10)(q) Apoptosis via MAPK activation, DNA damage response 
via ATM
RET/PTC2 Protein kinase cAMP-dependent 
type I regulatory subunit alpha
PRKAR1A (also known 
as CAR)
t(10;17) Regulatory subunit of protein kinase A
RET/PTC3, 
RET/PTC4
Nuclear receptor coactivator 4 NCOA4 (also known as ELE1) inv(10)(q) Nutrient (protein, lipid, glucose) recycling via autophagy; 
reduces cell proliferation; NCOA4 is a coactivator of PPARγ
RET/PTC5 Golgin A5 GOLGA5 (also known as RFG5) t(10;14) Golgi apparatus maintenance and its reassembly af-
ter mitosis
RET/PTC6 Tripartite motif family member 24 TRIM24 (also known as PTC6) t(10;7) Regulates p53 functions: p53-dependent apoptosis and 
DNA damage response
RET/PTC7 Tripartite motif family member 33 TRIM33 (also known as RFG7) t(10;1) Major interacting partner of TRIM24
RET/PTC8 Kinectin 1 (kinesin receptor) KTN1(also known as CG1) t10;14) Intracellular organelle motility
RET/PTC9 Methyl-CpG-binding domain protein 1 MBD1(also known as RFT) t(10;18) Repression of transcription from methylated gene promoters
CCDC6/PTEN Phosphatase and tensin homolog PTEN inv(10)(q) Tumor suppression, mitochondrial energy metabolism, cell 
cycle control, cell survival
AKAP9/BRAF A-kinase anchoring protein 9 AKAP9 (also known as LQT11) inv(7)(q) Assembles several protein kinases and phosphatases on the 
centrosome and the Golgi apparatus
AGK/BRAF Acylglycerol kinase AGK (also known as MULK) inv(7)(q) Mitochondrial membrane protein, lipid metabolism
TPR/NTRK1 Translocated promoter region, nu-
clear basket protein
TPR inv(1)(q) Nucleo-cytoplasmic transport of proteins and mRNAs, plays 
a role in interphase, and in the mitotic spindle checkpoint 
signaling during mitosis
ETV6/NTRK3 ETS variant 6 ETV6 (also known as TEL) t(15;12) Signal-dependent transcriptional regulator of differen-
tiation, cell cycle control, migration, proliferation, and 
apoptosis
CREB3L2/
PPARγ
cAMP-responsive element-binding 
protein 3-like protein 2
CREB3L2 (also known 
as BBF2H7)
t(3;7) ER membrane resident protein; upon ER stress, transloca ted 
to the Golgi apparatus where it is cleaved and the fragment 
is transported into the nucleus
PAX8/PPARγ Paired box 8 PAX8 t(2;3) Transcription factor; a role in binding to DNA and regulating 
the genes that drive thyroid cell growth
CLIP2 CAP-Gly domain containing link-
er protein 2
CLIP2 (self) amp(7)(q) Cytoplasmic linker protein; involved in apoptosis via an inter-
action with Bcl-2 associated athanogene 2 (BAG2), a protein 
that binds to BCL-2, enhancing BCL-2 anti-apoptotic activity
Note: amp(*) — amplification; ATM — ataxia telangiectasia mutated (ATM serine/threonine kinase); BRAF — B-Raf protooncogene (serine/threonine kinase); ER — 
endoplasmic reticulum; inv(*) — intrachromosomal inversion; MAPK — mitogen-activated protein kinase; NTRK — neurotropic receptor tyrosine kinase; PPARγ — 
peroxisome proliferator activated receptor gamma; PTC — papillary thyroid cancer; RET — rearranged during transfection; t(*;*) — interchromosomal translocation.
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in Ukrainian patients [99], also analyzed by Dinets and 
colleagues [98]. Independently, Xu et al. [100] applied 
a machine learning method to re-examine the previously 
published transcriptome data [101] in order to identify 
a diagnostic marker of thyroid cancers. According to the 
authors, the overexpression of BCL2 at mRNA level 
is the most statistically significant among a nine gene-
signature that discriminates between thyroid cancers 
and the normal thyroid [100]. It would seem then the 
BCL2 overexpression may serve as a diagnostic marker 
but not a marker of the post-Chornobyl thyroid cancers.
Several groups studied gene expression profiles 
(for example [86,102–104]) in biological samples from 
the Chernobyl Tissue Bank [87]. While the authors 
generally reported “subtle, but significant differences 
in gene expression” [103] between Chornobyl radiation-
exposed vs. sporadic groups, there was no overlap 
of genes among different studies. An interesting 
result in [102] is differential transcriptional signaling 
related to proliferation and apoptosis between radiation-
exposed and non-exposed normal thyroid tissues. 
An imbalance between cell death and growth favor-
ing the latter is one of hallmarks of cancer [17]. Dom 
and co-workers [102] used the Kyoto Encyclopedia 
of Genes and Genomes (KEGG) database [105] to clas-
sify differentially expressed genes into their respective 
functional pathways. Two of eleven KEGG pathways, 
hsa04210 and hsa04010, respectively, regulate apop-
tosis and proliferation via the MAPK signaling pathway 
[102]. The authors associate the activation of these 
pathways to global late effects of β-radiation (Table 1) 
on the normal thyroid epithelium. However, the MAPK 
and apoptotic pathways are known to be significantly 
deregulated in the Chornobyl thyroid cancers by genetic 
alterations, such as the formation of kinase fusion on-
cogenes, RETPTC and ETV6/NTRK3, and copy number 
gain and resulting overexpression of CLIP2 (Table 3). 
The CLIP2 first neighborhood network includes the 
anti-apoptotic BAG2 gene (BCL2-associated atha-
nogene) [106], whose anti-cell death activity may 
be enhanced by the amplification of CLIP2 in RET/
PTC-positive thyroid cancers [80, 84, 85]. The other 
CLIP2 partner in the network is neuralized E3 ubiquitin 
protein ligase 1 (NEURL1), which has a pro-apoptotic 
activity via the NOTCH1 signaling pathway which itself 
is activated by the MAPK signaling pathway [107,108]. 
As discussed earlier, cancer cells evolved to tolerate 
multi-level abnormalities (translocations, misrepaired 
DNA damage, etc.) favoring survival and proliferation 
because these defects drive the carcinogenic process. 
In contrast, normal cells are programmed to commit 
suicide (apoptosis) in response to such abnormalities, 
perhaps as a protective mechanism against cancer. 
Dom et al. [102] findings seem to be at odds with these 
established concepts at least as applied to Chornobyl 
fallout thyroid carcinogenesis.
Hematologic malignancies
The possible leukemogenic effects of X-rays 
were recognized more than a century ago (for review, 
see [109]). To date, there are several statistically valid 
epidemiological studies estimating radiogenic risks for 
hematological cancer incidence and mortality. In par-
ticular, it was shown that both acute and protracted ion-
izing radiation exposures among the Japanese A-bomb 
survivors (Life Span Study (LSS) cohort) [110] and the 
Techa River cohort (28,223 persons) [111] were asso-
ciated with increased incidence rates for leukemia and 
other hematological malignances. In addition, leukemia 
MAPK
ATM
PP4C CREB1CCDC6
Apoptosis via stress-responsive MAPK cascade
that includes p53
DNA damage recognition and responses 
via downstream genes, including TP53 and p53 network
Transcription factor; 
it binds to cAMP-responsive element 
in DNA and regulates expression 
of several downstream genes 
including those coding 
for pro-apoptotic proteins
DNA damage checkpoint recovery;
DNA repair;
stimulates NF-κB activity
Fig. 2. The CCDC6 regulatory network. ATM — ataxia telangiectasia mutated (ATM serine/threonine kinase); CREB1 — cAMP-responsive 
element-binding protein 1; MAPK — mitogen-activated protein kinase; PP4C –protein phosphatase 4 catalytic subunit.
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mortality risks among workers at the Mayak nuclear 
complex (about 21,500 persons) and 90,268 US radio-
logical technologists were also well documented [112, 
113]. The LSS with 93,741 survivors of A-bombing and 
26,580 non-exposed Hiroshima and Nagasaki residents 
represents one of the largest epidemiological study 
of radiation-exposed population with long-term follow-
up (since 1950) with most informative data on personal 
dose estimates.
The overall conclusions from analyses of hemato-
logical malignancies in the LSS cohort can be sum-
marized as follows: (i) radiation-induced leukemia 
occurred 2 to 3 years after exposure, reached its peak 
within 6 to 8 years after the bombing, and then declined 
steadily; (ii) while leukemia accounts for only about 3% 
of all cancer deaths in the LSS, it represents more than 
20% of the excess cancer deaths (between 1950 and 
1990); (iii) for those exposed as children essentially all 
of the excess leukemia deaths appear to have been 
early in the follow-up; (iv) in contrast to solid cancers, 
the dose response for leukemias is nonlinear (see 
above); (v) the radiation-associated leukemia risks have 
decreased over time, however dose-related increased 
risks, especially for acute myeloid leukemia (AML), 
may persist for many years after ionizing radiation 
exposure; (vi) earlier findings of radiation-associated 
excess risk for multiple myeloma (MM) have not been 
confirmed [110, 114].
The incidence of leukemia and other hemato-
logical malignancies in the most exposed popula-
tions in Ukraine, the Russian Federation, and Belarus 
is among the major objectives of epidemiological stu-
dies on the long-term effects of the Chornobyl accident. 
The joint Ukrainian-American study of leukemia and 
related disorders among Chornobyl cleanup workers 
based on the estimation of a cohort of 110,645 male 
workers demonstrated a significant positive association 
between leukemia incidence and continuous radiation 
dose (excess relative risk (ERR)/Gy = 1.26) [115]. This 
case-control study has also identified elevated radiation 
risks among Ukrainian cleanup workers for both CLL and 
non-CLL cases (ERR/Gy = 2.58 and 2.21, respectively). 
For a long period of time, CLL was not considered 
as radiation-associated leukemia. However, in recent 
years this view has changed and now CLL radiogenicity 
is strongly suspected [116–119]. The excess risk of leu-
kemia incidence for the period 1986–1997 in Russian 
cohort of the Chornobyl liquidators with doses above 
150 mGy has been also found [120]. Similarly, Rozhko 
et al. [121] recently observed an increase of standard-
ized incidence ratios (SIR; the ratio of the observed 
to the expected number of cancer cases) for acute 
lymphoblastic leukemia (ALL; SIR = 1.7), CLL (SIR = 
1.4), and chronic myeloid leukemia (CML; SIR = 2.0) 
in a cohort of 99,693 cleanup workers from Belarus over 
the whole post-Chornobyl period. Of note, increased 
risks of leukemia among both Ukrainian and Russian 
cleanup workers were consistent with estimates for the 
Japanese atomic bomb victims [115, 120]. In addition, 
the significant excess of MM incidence (SIR = 1.61) 
in a cohort of 152,520 male Ukrainian Chornobyl liquida-
tors in comparison with general population of Ukraine 
of corresponding age and gender has been recently 
identified [122]. Another report has suggested that my-
elodysplastic syndromes (MDS) percentage in patients 
with hematological malignancies among Chornobyl 
cleanup workers (1986–1987) was higher than in the 
patients from the general population of Ukraine over 
the same period (5.4% vs. 3.7%) [123].
In contrast to Chornobyl recovery workers, data 
on the leukemia incidence among the residents of the 
radioactively contaminated territories of Ukraine, the 
Russian Federation, and Belarus have been contradic-
tory. For example, the risk for childhood leukemia was 
associated with the dose of ionizing radiation exposure 
in Ukraine and in Belarus but not in Russia [124]. In two 
recent screening cohort studies in Ukraine and Belarus 
no convincing evidence of long-term risks of leuke-
mia after exposure to Chornobyl fallout has been 
found [125, 126]. On the other hand, there are several 
reports indicating an increased incidence rates of leu-
kemia among both children and adults living in the most 
heavily contaminated areas of Ukraine, the Russian 
Federation, and Belarus (reviewed in [127]), although 
statistical power of those data is unclear.
As mentioned above, much interest in recent years 
has been focused on the search for molecular markers 
of cancer associated with ionizing radiation exposure. 
In particular, a number of apoptotic markers were 
investigated in leukemia and other hematological ma-
lignant diseases among persons exposed to radiation 
from Chornobyl fallout. It was found that leukemia cells 
in Chornobyl-affected AML cases more often overex-
pressed antiapoptotic BCL-2 (12/21 vs. 6/35; p < 0.05) 
and less often demonstrated expression of FAS death 
receptor (12/21 vs. 30/35; p < 0.05) [128]. Moreover, 
BCL-2+/FAS– cells were found in four out of 21 ionizing 
radiation-exposed AML patients but in none of 35 AML 
cases with no history of irradiation. In a similar study, up-
regulation of BCL-2 gene has been reported in Ukrainian 
patients diagnosed with leukemia in post-Chornobyl 
period [129]. Because BCL-2 expression level in Ukrai-
nian leukemia patients is superior to that of proapoptotic 
BAX, it is tempting to speculate that anti-death activity 
of BCL-2 may be responsible for the excessive accu-
mulation of leukemia cells due to abnormal apoptosis. 
Further studies are needed to verify this hypothesis.
It is well known that reciprocal translocation between 
chromosome 9 and chromosome 22 results in genera-
tion of the chimeric BCR-ABL gene detected in all CML 
cases and some acute leukemias. The BCR-ABL fusion 
protein is a constitutively activated tyrosine kinase with 
a variety of biological activities, including apoptosis 
inhibition. The anti-apoptotic function of BCR-ABL 
is mediated by increasing expression of Bcl-xL, pre-
venting Bax and Bad translocation to mitochondria, 
and inhibiting APAF-1 binding to caspase-9 [130, 131]. 
Klymenko et al. [132] assessed BCR-ABL status in in-
terphase leukemia cells of 33 AML patients (13 Chor-
nobyl radiation-exposed persons and 20 persons with 
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spontaneous disease) by FISH analysis. Four BCR-ABL 
positive cases were found in AML patients among Chor-
nobyl-affected persons, while only one such case was 
present in an unexposed group. Allelic polymorphism 
of the BCR gene in peripheral blood mononuclear cells 
from 36 Ukrainian Chornobyl cleanup workers with the 
total radiation doses in the range of 5.1–75.0 cGy was 
also studied using Southern blot hybridization [133]. 
In 6 cases, an extra 8.3-kb fragment was detected 
in addition to the standard 4.3-kb HindIII fragment 
suggesting BCR rearrangement; also the presence 
of the BCR-ABL fusion gene was not assessed in that 
study. Such allelic polymorphism of the BCR gene has 
been never observed in healthy persons who were not 
exposed to ionizing radiation. Collectively, these data 
provide a new insight into the leukemia-associated 
genetic aberrations in Chornobyl cleanup workers long 
after irradiation and warrant further research.
Telomeres were identified in classical genetics 
as specific DNA tandem repeats (TTAGGG)n, which cap 
the ends of chromosomes and protect cells against 
both unwanted fusion between chromosomes and 
apoptotic cell death. Exposure to ionizing radiation 
mainly at higher doses is known to modulate telomere 
length. However, the response of telomere length 
to protracted irradiation is still debatable and not fully 
conclusive. The effects of low-dose ionizing radiation 
on the telomere length and apoptosis rates in peripheral 
blood lymphocytes of 73 persons irradiated as a result 
of the Chornobyl accident were analyzed using flow-
FISH assay and flow cytometry [134]. The authors 
found a statistically significant telomere length decrease 
in a group of Chornobyl cleanup workers compared 
to healthy volunteers. It should be noted that apoptosis 
rates increased in lymphocytes with shorter telomeres. 
Since these changes persisted for 20 years post initial 
exposure, presented results point to the possible role 
for telomere length erosion in modulating apoptosis late 
after irradiation. In marked contrast, longer telomeres 
were found in patients with MDS developed after ex-
posure to Chornobyl low-dose ionizing radiation [134]. 
In those cases, elongation of telomere length was as-
sociated with decreased apoptosis induction. The telo-
mere length modulation in Chornobyl accident recovery 
workers was recently examined by another research 
team [135]. The results showed that the longest telo-
meres were observed in cleanup workers with malignan-
cies. Furthermore, individuals with longer telomeres had 
almost twice the cancer risk compared to persons with 
shorter telomeres. Although these studies were limited, 
one way to interpret the above-mentioned data is that 
chronic low-dose ionizing radiation exposure might in-
crease in vivo susceptibility to malignant transformation 
due to telomere lengthening.
During the last decades, the novel apoptotic play-
ers such as highly conserved small non-protein coding 
single-stranded miRNAs (also called miRs) that display 
their effects by directly targeting both pro- and anti-
apoptotic genes have been extensively investigated. 
The disco very of the relationship between miRNAs 
expression, ioni zing radiation exposure, and tumor 
radioresistance has broadened the avenue in both ra-
diobiology and cancer research (for review, see [136]). 
Although miRNA profiling among Chornobyl cleanup 
workers or among individuals inhabiting radioactively 
contaminated areas in post-Chornobyl period has not 
yet been performed, several other radiation exposed 
cohorts were under study. For example, the miRNA ex-
pression profiles were analyzed to elucidate the differ-
entially expressed miRNAs in the high- or low-exposed 
atomic bomb survivors with gastric cancer (GC) [137]. 
It was found that the expression levels of miR-21, miR-
24, miR-34a, miR-106a, miR-143, and miR-145 were 
significantly higher in GC from high-exposed patients 
than in GC from low dose-exposed patients; but only 
miR-24 high expression was an independent marker 
for exposure status by multivariate analysis. Interes-
tingly, proapoptotic BCL2L11 gene was recently verified 
as a direct functional target of miR-24 and downregula-
tion of BCL2L11 mRNA results in cell growth promotion 
and apoptosis inhibition in GC [138]. Another study 
focused on comparative analysis of miRNA expression 
profiles in whole blood samples collected from Mayak 
workers occupationally exposed to prolonged radiation 
or unexposed individuals [139]. As a result, 45 differen-
tially expressed miRNAs were identified, among which 
were several miRNAs (e.g., miR-21, miR-145, miR-199a, 
and miR-378) responsible for apoptosis regulation. Re-
cent functional in vitro studies [140] provide evidence 
that sub-G1 apoptotic fraction of radioresistant cancer 
cells increased markedly after irradiation as a result 
of miR-21 knockdown. Overall, potential association 
of specific miRNAs expression with radiation-induced 
cancer merits further consideration.
CONCLUDING REMARKS
The Chornobyl accident is a man-made disaster 
of unparalleled proportions in terms of the magnitude 
of the radioactive releases and the size of the exposed 
populations. The exposed populations that received 
radiation doses include emergency and recovery opera-
tion workers and the general population that either evac-
uated from the areas in the vicinity of Chornobyl shortly 
after the accident or continued living in the contaminated 
areas of Belarus, the Russian Federation, and Ukraine. 
The radiological consequences of the Chornobyl ac-
cident on health of the exposed populations have been 
subject of numerous experimental and analytical studies 
in the past 30 years. These studies provided important 
new information on links between internal or external 
exposure to radiation in childhood or adulthood and 
cancer outbreak, and have been reviewed here. Our 
particular focus has been an overview of cytogenetic 
and molecular research of Chornobyl thyroid cancer 
and hematopoietic malignancies wherein cancer epi-
demiology provided the clear quantitative relationship 
between radiation dose and cancer risk for identifiable 
groups of exposed individuals (Table 4). We highlight 
a role of apoptosis as a mediator of tumor suppression 
in the irradiated thyroid or hematopoietic/lymphoid tis-
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sues as an example of radiation-induced mechanisms 
that restrain the growth or eliminate aberrant cells.
Table 4. To-date (November 2016) summary of findings on radioactive fall-
out and cancer risk following the 1986 nuclear power plant accident in Chor-
nobyl
Exposed population Thyroid cancer Leukemia
Recovery operation workers Equivocal Positive
Inhabitants of contaminated areas:
Children
In utero
Adults
Positive
Negative
Negative
Negative
Equivocal
Negative
The repertoire of tumor suppressive mechanisms in-
cludes cell cycle arrest, cellular senescence, apoptosis 
and other molecularly-defined modes of cell death [32] 
as well as maintaining genome stability. These process-
es are regulated by separate but intertwined pathways 
utilized in a cell type-specific manner. In regard to apop-
tosis, “BCL-2-regulated” (also termed “intrinsic”, “mi-
tochondrial” or “stress-induced”) signaling pathway 
(Fig. 1) may be activated in both irradiated thyroid and 
hematopoietic tissues whereas cell surface “death re-
ceptor” signaling pathway (Fig. 1) may be activated only 
in hematopoietic/lymphoid tissues. Mutations in FAS 
and its ligand FASL may lead to lymphadenopathy and 
leukemia observed in Chornobyl cleanup workers.
Control of apoptosis and progression of the cell cycle 
are linked processes. This is exemplified by a dual role 
of several proteins associated with radiation-induced 
thyroid carcinogenesis (Table 3). The partner genes 
in fusion genes, CLIP2 and their first neighbors are es-
sential for proper chromosome segregation, cytokinesis 
and the regulation of microtubule dynamics. Dysregu-
lation of these processes leads to improper chromo-
some segregation in cell division and, in turn, mitotic 
catastrophe or apoptosis. The importance of the MAPK 
pathway, which plays a fundamental role in proliferation, 
has been well established in Chornobyl thyroid tumors 
with rearrangements of the RET, BRAF and NTRK 
genes, and CLIP2 amplification as well as in Chornobyl 
leukemia in Ukrainian patients. RET/PTC1 affects the 
activity of NF-κB via association of CCDC6 with phos-
phatase PP4C (Fig. 2). Normally, NF-κB drives cellular 
proliferation but also promotes cell survival in part via 
transcriptional induction of anti-apoptotic BCL-2 family 
members (BCL-2 and BCL-XL) as well as several IAPs 
(Fig. 1). The IAP member survivin, known as the fourth 
most highly expressed protein in human cancer [141], 
shares functionality with CLIP2. Like CLIP2, survivin lo-
calizes to the mitotic spindle by interaction with tubulin 
during mitosis but unlike CLIP2 it also plays a contrib-
uting role in regulating apoptosis in G2/M phase. The 
overexpression of survivin in cancer may overcome 
this apoptotic checkpoint and favor aberrant progres-
sion of transformed cells through mitosis. Survivin 
expression can be deregulated in cancer by several 
mechanisms, including amplification of the survivin 
locus on chromosome 17q25 and increased upstream 
signaling in the MAPK or phosphatidylinositol 3-kinase 
pathways.
The identification of somatic mutations and the 
cancer genes that they alter has been a central aim 
of cancer research in radiation biology for more than 
a half of a century. In the case of thyroid cancer, the 
search for “the radiation signature” is greatly facilitated 
by the resources of the Chernobyl Tissue Bank, which 
systematically collects biological samples from tumors 
and normal tissues from patients with radiation-related 
thyroid pathology. Perhaps the most important finding 
to date, possibly generalizable to other tissues, is that 
the type of mutations due to DNA double strand breaks 
(gene fusion and amplification) is the initial signature 
event in radiation-induced tumors; this is in contrast 
to spontaneous tumors that typically harbor point mu-
tations (base substitutions, small deletions and inser-
tions). For clarity, point mutations — hitting a specific 
nucleotide base by chance — are highly improbable 
(the event probability of the order of 10–9) considering 
the physical size of the human genome and random 
pattern/density of ionizations impinging on DNA. This 
is nicely illustrated by pathological and genetic analyses 
of Fukushima thyroid cancers showing high frequency 
of BRAFV600E mutation and background levels of chromo-
some rearrangements, consistent with non-radiogenic 
etiology [58].
In conclusion, studies of populations exposed to ra-
diation as the result of the Chornobyl accident provided 
increased knowledge of the molecular pathogenesis 
of thyroid tumors following exposure to iodine isotopes. 
Recent studies among Chornobyl liquidators have also 
provided evidence of increases in the risk of leukemia 
and other hematopoietic malignancies. Upward trends 
have been reported, often anecdotally, of increases 
in a variety of other tumors in those exposed to Chor-
nobyl fallout (Table 4), including breast, brain and kid-
ney. The progress to date has been possible because 
of past and on-going efforts of many experts from 
within and outside the most affected areas who worked 
to evaluate the radiological impact of the catastrophe 
over the first thirty years post Chornobyl. There is, how-
ever, much work to be done over the next years and even 
decades. In a manner similar to life-span studies of the 
atomic bomb survivors, the coordinate multidisciplinary 
work needs to continue internally to monitor sensitive 
populations such as young women at a risk of breast 
cancer, to maximize use of resources such as Chernobyl 
Tissue Bank and minimize duplication of efforts such 
as microarray studies. With further technological ad-
vances in transcriptomic, proteomic, and metabolomic 
profiling we can realistically expect to elucidate central 
questions related to the nature of human radiation car-
cinogenesis in a near future.
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